Trial Profile

Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults, Children and Infants, Lot to Lot Consistency, Non-inferiority to PQed (Prequalified) TCV (Typhoid Conjugate Vaccine)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Typhoid vaccine Vi DT conjugate International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma (Primary) ; Typhoid vaccine Vi conjugate; Vi polysaccharide typhoid vaccine (vax-TyVi)
Indications Typhoid
Focus Pharmacodynamics; Registrational
Sponsors PT Bio Farma

30 Dec 2021 Status changed from recruiting to completed.
04 Oct 2021 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
04 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Nov 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com